DOCSLIB.ORG

Urinary System Tumor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Urinary System Tumor 1A028 Urinary System U Editors: rinary rinary Tumor Dingwei Ye, Philippe E. Spiess, Simon Horenblas Dingwei Ye, www.amegroups.com Editors: Dingwei Ye, Philippe E. Spiess, Simon Horenblas S Associate Editors: Yao Zhu, ystem Siamak Daneshmand, Badrinath R. Konety, Maarten Albersen T umor amegroups.com ￥685.00 Urinary System Tumor Editors: Dingwei Ye, Philippe E. Spiess, Simon Horenblas Associate Editors: Yao Zhu, Siamak Daneshmand, Badrinath R. Konety, Maarten Albersen AME Publishing Company Room C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong Information on this title: www.amegroups.com For more information, contact [email protected] Copyright © AME Publishing Company. All rights reserved. This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of AME Publishing Company. First published in 2017 Printed in China by AME Publishing Company and Central South University Press Editors: Dingwei Ye, Philippe E. Spiess, Simon Horenblas Cover Image Illustrator: Xuefei Yang, Shenzhen, China URINARY SYSTEM TUMOR (Hard Cover) ISBN: 978-988-77841-3-5 AME Publishing Company, Hong Kong ISBN: 978-7-5487-3025-5 Central South University Press, Changsha AME Publishing Company and Central South University Press have no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and do not guarantee that any content on such websites is, or will remain, accurate or appropriate. The advice and opinions expressed in this book are solely those of the authors and do not necessarily represent the views or practices of the publishers. No representations are made by the publishers about the suitability of the information contained in this book, and there is no consent, endorsement or recommendation provided by the publishers, express or implied, with regard to its contents. I URINARY SYSTEM TUMOR (FIRST EDITION) Editors Authors Dingwei Ye Mehrad Adibi Department of Urology, Fudan University Shanghai Cancer Department of Urology, The University of Texas M.D. Center, Shanghai, China Anderson Cancer Center, Houston, USA Philippe E. Spiess Ashok Agarwal Department of Genitourinary Oncology, Moffitt Cancer Center for Reproductive Medicine, Glickman Urological & Center, Tampa, FL, USA Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA Simon Horenblas Nusret Akpolat Department of Urology, Netherlands Cancer Institute, Inonu University Faculty of Medicine, Department of Amsterdam, The Netherlands Pathology, Malatya, Turkey Associate Editors Isabelle Avildsen Department of Psychiatry and Behavioral Sciences, Yao Zhu Memorial Sloan-Kettering Cancer Center, New York, USA Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China Steven P. Balk Hematology-Oncology Division, Department of Medicine, Siamak Daneshmand Beth Israel Deaconess Medical Center, Harvard Medical Institute of Urology, USC/Norris Comprehensive Cancer School, Boston, MA 02215, USA Center, Los Angeles, CA, USA Jack Baniel Badrinath R. Konety Department of Urology, Rabin Medical Centre Beilinson Department of Urology, University of Minnesota, Campus, Petah Tiqwa, Israel; Sackler Medical School, Tel Minneapolis, MN, USA. Aviv University, P.O. Box 39040, Tel Aviv 69978, Israel Maarten Albersen Roberto Barbieri Department of Urology, University Hospitals Leuven, Oncology Unit, “Carlo Poma” Hospital, Mantua, Italy Leuven, Belgium Karim Bensalah Department of Urology, Rennes University Hospital, Rennes, France Marco Bianchi Unit of Urology/Department of Oncology, URI, IRCCS San Raffaele Hospital, Milan, Italy II Sharon L. Bober Camilla Casi Dana-Farber Cancer Institute, Brigham and Women’s Medical Oncology Division, Medical Oncology Hospital and Harvard Medical School, Boston, Department, Val d’Elsa Hospital, Siena, Italy Massachusetts, USA Thenappan Chandrasekar Leonardo D. Borregales Department of Urology, University of California, Davis, Department of Urology, The University of Texas M.D. CA, USA Anderson Cancer Center, Houston, USA Costanza Chiumento Benjamin N. Breyer Department of Radiation Oncology, IRCCS-CROB, Department of Urology, University of California, San Rionero in Vulture 85028, Italy Francisco, San Francisco General Hospital, San Francisco, CA 94117, USA Sameer Chopra USC Institute of Urology, Catherine & Joseph Aresty Alberto Briganti Department of Urology, Keck School of Medicine, Unit of Urology/Department of Oncology, URI, IRCCS University of Southern California, Los Angeles, CA 90089, San Raffaele Hospital, Milan, Italy USA Gerald Brock Leland W.K. Chung University of Western Ontario, London, Ontario, Canada Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA Changmeng Cai 90048, USA Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical Nadya M. Cinman School, Boston, MA 02215, USA Department of Urology, University of California, San Francisco, San Francisco General Hospital, San Francisco, Rocchina Caivano CA 94117, USA Department of Radiation Oncology, IRCCS-CROB, Rionero in Vulture 85028, Italy Giacomo Ciocca Department of Biotechnological and Applied Clinical Katie Canalichio Sciences, University of L’Aquila, L’Aquila, Italy Division of Urology, University of Texas Health Science Center, Houston, TX 77030, USA Stefania Clemente Department of Radiation Oncology, IRCCS-CROB, Eleonora Carosa Rionero in Vulture 85028, Italy Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy Mariella Cozzolino Department of Radiation Oncology, IRCCS-CROB, Peter R. Carroll Rionero in Vulture 85028, Italy UCSF Helen Diller Family Comprehensive Cancer Center, Department of Urology, University of California San Vito Cucchiara Francisco, San Francisco, CA 94143, USA Unit of Urology/Department of Oncology, URI, IRCCS San Raffaele Hospital, Milan, Italy Brett S. Carver Department of Surgery, Division of Urology, Memorial Atreya Dash Sloan-Kettering Cancer Center, New York, USA Department of Urology, the University of California at Irvine, CA 92868, USA III Brenda Den Oudsten Zhaoyan Feng Center of Research on Psychology in Somatic Diseases, Department of Radiology, Tongji Hospital, Tongji Medical Department of Medical and Clinical Psychology, Tilburg College, Huazhong University of Science and Technology, University, PO Box 90153, 5000 LE, Tilburg, The Wuhan 430030, China Netherlands Alba Fiorentino Ernesto Di Cesare Department of Radiation Oncology, IRCCS-CROB, Department of Biotechnological and Applied Clinical Rionero in Vulture 85028, Italy Sciences, Division of Radiotherapy, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, Italy Stefanie Fischer Division of Oncology/Haematology, Kantonsspital St. Stefania Di Sante Gallen, 9007 St. Gallen, Switzerland Department of Experimental Medicine, Sapienza University of Rome, Roma, Italy Liz Forbat Australian Catholic University, Canberra, Australia Colin P. N. Dinney Department of Urology, MD Anderson Cancer Center, Vincenzo Fusco Houston, TX 77030, USA Department of Radiation Oncology, IRCCS-CROB, Rionero in Vulture 85028, Italy Damayanthi Durairajanayagam Center for Reproductive Medicine, Glickman Urological & Giorgio Gandaglia Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA Unit of Urology/Department of Oncology, URI, IRCCS San Raffaele Hospital, Milan, Italy Yaron Ehrlich Department of Urology, Rabin Medical Centre Beilinson Allen C. Gao Campus, Petah Tiqwa, Israel Department of Urology, University of California, Davis, CA, USA Kurtis Eisermann Department of Urology, University of Pittsburgh School of Inderbir S. Gill Medicine, Pittsburgh, Pennsylvania, 15232, USA USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, Jessica C. Emanu University of Southern California, Los Angeles, CA 90089, Department of Psychiatry and Behavioral Sciences, USA Memorial Sloan-Kettering Cancer Center, New York, USA Silke Gillessen Meltem Esen Division of Oncology/Haematology, Kantonsspital St. Department of Radiology, Inegol Government Hospital, Gallen, 9007 St. Gallen, Switzerland Bursa, Turkey Allison S. Glass Christopher P. Evans Department of Urology, University of California, San Department of Urology, University of California, Davis, Francisco, San Francisco General Hospital, San Francisco, CA, USA CA 94117, USA Roberta Falchi Martin E. Gleave Nuclear Medicine Division, Fondazione Poliambulanza Vancouver Prostate Centre, University of British Columbia, Istituto Ospedaliero, Brescia, Italy Vancouver, BC, Canada IV Campbell M. Grant Jer-Tsong Hsieh Departments of Urology, Molecular Biochemistry, and Departments of Urology, University of Texas Southwestern Pathology, University of Kentucky College of Medicine and Medical Center, Dallas, TX 75390, USA the Markey Cancer Center, Lexington, Kentucky, USA Zhiquan Hu Giovanni L. Gravina Department of Urology, Tongji Hospital, Tongji Medical Department of Biotechnological and Applied Clinical College, Huazhong University of Science and Technology, Sciences, University of L’Aquila, L’Aquila, Italy; Department Wuhan 430030, China of Experimental Medicine, Sapienza University of Rome, Roma, Italy; Department of Biotechnological and Applied Daoyu Hu Clinical Sciences, Division of Radiotherapy, Laboratory of Department of Radiology, Tongji
Load more

Recommended publications
  • Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer
    International Journal of Molecular Sciences Review Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer Jun Yang 1,* ID , Adrian L. Harris 2 and Andrew M. Davidoff 1 1 Department of Surgery, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA; [email protected] 2 Molecular Oncology Laboratories, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; [email protected] * Correspondence: [email protected] Received: 19 December 2017; Accepted: 9 January 2018; Published: 13 January 2018 Abstract: Hormones play an important role in pathophysiology. The hormone receptors, such as estrogen receptor alpha and androgen receptor in breast cancer and prostate cancer, are critical to cancer cell proliferation and tumor growth. In this review we focused on the cross-talk between hormone and hypoxia pathways, particularly in breast cancer. We delineated a novel signaling pathway from estrogen receptor to hypoxia-inducible factor 1, and discussed the role of this pathway in endocrine therapy resistance. Further, we discussed the estrogen and hypoxia pathways converging at histone demethylase KDM4B, an important epigenetic modifier in cancer. Keywords: estrogen receptor alpha; hypoxia-inducible factor 1; KDM4B; endocrine therapy resistance 1. Introduction A solid tumor is a heterogeneous mass that is comprised of not only genetically and epigenetically distinct clones, but also of areas with varying degree of hypoxia that result from rapid cancer cell proliferation that outgrows its blood supply. To survive in hostile hypoxic environments, cancer cells decelerate their proliferation rate, alter metabolism and cellular pH, and induce angiogenesis [1].
    [Show full text]
  • Long Noncoding RNA and Cancer: a New Paradigm Arunoday Bhan, Milad Soleimani, and Subhrangsu S
    Published OnlineFirst July 12, 2017; DOI: 10.1158/0008-5472.CAN-16-2634 Cancer Review Research Long Noncoding RNA and Cancer: A New Paradigm Arunoday Bhan, Milad Soleimani, and Subhrangsu S. Mandal Abstract In addition to mutations or aberrant expression in the moting (oncogenic) functions. Because of their genome-wide protein-coding genes, mutations and misregulation of noncod- expression patterns in a variety of tissues and their tissue- ing RNAs, in particular long noncoding RNAs (lncRNA), appear specific expression characteristics, lncRNAs hold strong prom- to play major roles in cancer. Genome-wide association studies ise as novel biomarkers and therapeutic targets for cancer. In of tumor samples have identified a large number of lncRNAs this article, we have reviewed the emerging functions and associated with various types of cancer. Alterations in lncRNA association of lncRNAs in different types of cancer and dis- expression and their mutations promote tumorigenesis and cussed their potential implications in cancer diagnosis and metastasis. LncRNAs may exhibit tumor-suppressive and -pro- therapy. Cancer Res; 77(15); 1–17. Ó2017 AACR. Introduction lncRNAs (lincRNA) originate from the region between two pro- tein-coding genes; enhancer lncRNAs (elncRNA) originate from Cancer is a complex disease associated with a variety of genetic the promoter enhancer regions; bidirectional lncRNAs are local- mutations, epigenetic alterations, chromosomal translocations, ized within the vicinity of a coding transcript of the opposite deletions, and amplification (1). Noncoding RNAs (ncRNA) are strand; sense-overlapping lncRNAs overlap with one or more an emerging class of transcripts that are coded by the genome but introns and exons of different protein-coding genes in the sense are mostly not translated into proteins (2).
    [Show full text]
  • Thermodynamic Quantities for the Ionization Reactions of Buffers
    Thermodynamic Quantities for the Ionization Reactions of Buffers Robert N. Goldberg,a… Nand Kishore,b… and Rebecca M. Lennen Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899 ͑Received 21 June 2001; accepted 16 September 2001; published 24 April 2002͒ This review contains selected values of thermodynamic quantities for the aqueous ionization reactions of 64 buffers, many of which are used in biological research. Since the aim is to be able to predict values of the ionization constant at temperatures not too far from ambient, the thermodynamic quantities which are tabulated are the pK, standard ⌬ ؠ ⌬ molar Gibbs energy rG , standard molar enthalpy rH°, and standard molar heat ca- ؠ ⌬ pacity change rC p for each of the ionization reactions at the temperature T ϭ298.15 K and the pressure pϭ0.1 MPa. The standard state is the hypothetical ideal solution of unit molality. The chemical name͑s͒ and CAS registry number, structure, empirical formula, and molecular weight are given for each buffer considered herein. The selection of the values of the thermodynamic quantities for each buffer is discussed. © 2002 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. Key words: buffers; enthalpy; equilibrium constant; evaluated data; Gibbs free energy; heat capacity; ionization; pK; thermodynamic properties. Contents 7.19. CAPSO.............................. 263 7.20. Carbonate............................ 264 7.21. CHES............................... 264 1. Introduction................................ 232 7.22. Citrate............................... 265 2. Thermodynamic Background.................. 233 7.23. L-Cysteine............................ 268 3. Presentation of Data......................... 234 7.24. Diethanolamine........................ 270 4. Evaluation of Data. ........................ 235 7.25. Diglycolate..........................
    [Show full text]
  • Buffers a Guide for the Preparation and Use of Buffers in Biological Systems Calbiochem® Buffers a Guide for the Preparation and Use of Buffers in Biological Systems
    Buffers A guide for the preparation and use of buffers in biological systems Calbiochem® Buffers A guide for the preparation and use of buffers in biological systems Chandra Mohan, Ph.D. EMD, San Diego, California © EMD, an affiliate of Merck KGaA, Darmstadt, Germany. All rights reserved. A word to our valued customers We are pleased to present to you the newest edition of Buffers: A Guide for the Preparation and Use of Buffers in Biological Systems. This practical resource has been especially revamped for use by researchers in the biological sciences. This publication is a part of our continuing commitment to provide useful product information and exceptional service to you, our customers. You will find this booklet a highly useful resource, whether you are just beginning your research work or training the newest researchers in your laboratory. Over the past several years, EMD Biosciences has clearly emerged as a world leader in providing highly innovative products for your research needs in Signal Transduction, including the areas of Cancer Biology, Alzheimer’s Disease, Diabetes, Hypertension, Inflammation, and Apoptosis. Please call us today for a free copy of our LATEST Catalog that includes tools for signal transduction and life science research. If you have used our products in the past, we thank you for your support and confidence in our products, and if you are just beginning your research career, please call us and give us the opportunity to demonstrate our exceptional customer and technical service. Corrine Fetherston Sr. Director, Marketing ii Table of Contents: Why does Calbiochem® Biochemicals Publish a Booklet on Buffers? .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,807,373 B2 Srivastava Et Al
    US007807373B2 (12) United States Patent (10) Patent No.: US 7,807,373 B2 Srivastava et al. (45) Date of Patent: Oct. 5, 2010 (54) PROSTATE SPECIFIC GENE, PCGEM1, AND GenBank. Accession No. ACO 13401, GI:8569780, 169700 bp DNA, METHODS OF USING PCEGM1 TO DETECT, Jul. 7, 2000. TREAT, AND PREVENT PROSTATE CANCER “AC003046.” EBI Database XPO02143197, Dec. 1, 2001. (75) Inventors: Shiv Srivastava, Potomac, MD (US); Srikantanet al., “Structure and Expression of a Novel Prostate Spe Judd W. Moul, Bethesda, MD (US); cific Gene: PCGEM1. Proc. American Assoc. Cancer Research Vasantha Srikantan, Rockville, MD Annual, XP000929230, vol. 40, p. 37 (Mar. 1999). (US); Zhiqiang Zou, Gaithersburg, MD Bussemakers et al., “A New Prostate-Specific Arker, Strongly (US) Overexpressed in Prostatic Tumors.” Urological Research, XP0020743.05, vol. 25, No. 1, p. 76 (Feb. 1997). (73) Assignee: Henry M. Jackson Foundation for the Wang et al., “Genes Regulated by Androgen in the Rat Ventral Pros Advancement of Military Medicine, tate.” Proc. Nat.1 Acad. Sci., U.S.A., vol. 94, pp. 12999-13004 (Nov. Rockville, MD (US) 1997). “ACO 13401, EBI Database XP002143200, Apr. 16, 2005. (*) Notice: Subject to any disclaimer, the term of this Srikantan et al., “PCGEM1, a Prostate-Specific Gene, Is Overex patent is extended or adjusted under 35 posed in Prostate Cancer.” Proc. Natl. Acad. Sci., vol.97, No. 22, pp. U.S.C. 154(b) by 285 days. 12216-12221 (Oct. 24, 2000). (21) Appl. No.: 12/166,723 Srikantan et al., Identification of Prostate Cancer Associated Novel Gene Expression Alterations, Proc. American Assoc. Cancer (22) Filed: Jul.
    [Show full text]
  • 2021 Western Medical Research Conference
    Abstracts J Investig Med: first published as 10.1136/jim-2021-WRMC on 21 December 2020. Downloaded from Genetics I Purpose of Study Genomic sequencing has identified a growing number of genes associated with developmental brain disorders Concurrent session and revealed the overlapping genetic architecture of autism spectrum disorder (ASD) and intellectual disability (ID). Chil- 8:10 AM dren with ASD are often identified first by psychologists or neurologists and the extent of genetic testing or genetics refer- Friday, January 29, 2021 ral is variable. Applying clinical whole genome sequencing (cWGS) early in the diagnostic process has the potential for timely molecular diagnosis and to circumvent the diagnostic 1 PROSPECTIVE STUDY OF EPILEPSY IN NGLY1 odyssey. Here we report a pilot study of cWGS in a clinical DEFICIENCY cohort of young children with ASD. RJ Levy*, CH Frater, WB Galentine, MR Ruzhnikov. Stanford University School of Medicine, Methods Used Children with ASD and cognitive delays/ID Stanford, CA were referred by neurologists or psychologists at a regional healthcare organization. Medical records were used to classify 10.1136/jim-2021-WRMC.1 probands as 1) ASD/ID or 2) complex ASD (defined as 1 or more major malformations, abnormal head circumference, or Purpose of Study To refine the electroclinical phenotype of dysmorphic features). cWGS was performed using either epilepsy in NGLY1 deficiency via prospective clinical and elec- parent-child trio (n=16) or parent-child-affected sibling (multi- troencephalogram (EEG) findings in an international cohort. plex families; n=3). Variants were classified according to Methods Used We performed prospective phenotyping of 28 ACMG guidelines.
    [Show full text]
  • Biological Buffers and Ultra Pure Reagents
    Biological Buffers and Ultra Pure Reagents Are MP Buffers in your corner? One Call. One Source. A World of Ultra Pure Biochemicals. www.mpbio.com Theoretical Considerations Since buffers are essential for controlling the pH in many Since, under equilibrium conditions, the rates of dissociation and biological and biochemical reactions, it is important to have a association must be equal, they may be expressed as: basic understanding of how buffers control the hydrogen ion concentration. Although a lengthy, detailed discussion is impractical, + - k1 (HAc) = k2 (H ) (Ac ) some explanation of the buffering phenomena is important. Or Let us begin with a discussion of the equilibrium constant (K) for + - weak acids and bases. Acids and bases which do not completely k1 = (H ) (Ac ) dissociate in solution, but instead exist as an equilibrium mixture of k (HAc) undissociated and dissociated species, are termed weak acids and 2 bases. The most common example of a weak acid is acetic acid. If we now let k1/k2 = Ka , the equilibrium constant, the equilibrium In solution, acetic acid exists as an equilibrium mixture of acetate expression becomes: ions, hydrogen ions, and undissociated acetic acid. The equilibrium between these species may be expressed as follows: + - Ka = (H ) (Ac ) k1 (HAc) + - HAc ⇌ H + Ac which may be rearranged to express the hydrogen ion concentration k2 in terms of the equilibrium constant and the concentrations of undissociated acetic acid and acetate ions as follows: where k1 is the dissociation rate constant of acetic acid to acetate and hydrogen ions and k is the association rate constant of the ion 2 (H+) = K (HAc) species to form acetic acid.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0030594 A1 ABRAMS Et Al
    US 2016.0030594A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0030594 A1 ABRAMS et al. (43) Pub. Date: Feb. 4, 2016 (54) ANTIBODY DRUG CONJUGATES Related U.S. Application Data (71) Applicants: Tinya ABRAMS, Acton, MA (US); (60) Provisional application No. 61/793,641, filed on Mar. Steven COHEN, San Diego, CA (US); 15, 2013. Christie P. FANTON, Oakland, CA EEEE): Publication Classification Kathy MILLER, San Francisco, CA (51) Int. Cl (US); Siew Ho SCHLEYER, El Cerrito, we CA (US); Kathrin Ulrike g 7. :08: TISSOT-DAGUETTE, Planegg (DE) A647/12 (2006.01) (72) Inventors: Tinya ABRAMS, Acton, MA (US); A647/26 (2006.01) Steven COHEN, San Diego, CA (US); A 6LX3/537 (2006.01) Christie P. FANTON, Oakland, CA A6II 45/06 (2006.01) (US); Catrin FINNER, Neuried (DE); (52) U.S. Cl. Thomas HUBER, Allschwil (CH): CPC. A61 K47/48561 (2013.01); A61K 47/48384 Kathy MILLER, San Francisco, CA (2013.01); A61 K3I/537 (2013.01); A61 K (US); Siew Ho SCHLEYER, El Cerrito, 45/06 (2013.01); A61 K47/12 (2013.01); A61 K CA (US); Kathrin Ulrike 47/26 (2013.01); A61 K47/4863 (2013.01); TISSOT-DAGUETTE, Planegg (DE) A61K47/48592 (2013.01); A61K 47/48615 (2013.01); C07K 16/32 (2013.01); C07K (21) Appl. No.: 14/774,512 231 7/565 (2013.01); C07K 231 7/24 (2013.01) (86). PCT No.: PCT/US14/24597 The present invention relates to anti-cKIT antibodies, anti S371 (c)(1), body fragments, antibody drug conjugates, and their uses for (2) Date: Sep.10, 2015 the treatment of cancer.
    [Show full text]
  • Oncotarget-05-764.Pdf
    Open Research Online The Open University’s repository of research publications and other research outputs Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer Journal Item How to cite: Crea, Francesco; Watahiki, Akira; Quagliata, Luca; Xue, Hui; Pikor, Larissa; Parolia, Abhijit; Wang, Yuwei; Lin, Dong; Lam, Wan L.; Farrar, William L.; Isogai, Takao; Morant, Rudolf; Castori-Eppenberger, Serenella; Chi, Kim N.; Wang, Yuzhuo and Helgason, Cheryl D. (2014). Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget, 5(3) pp. 764–774. For guidance on citations see FAQs. c 2014 The Authors https://creativecommons.org/licenses/by/4.0/ Version: Version of Record Link(s) to article on publisher’s website: http://dx.doi.org/doi:10.18632/oncotarget.1769 Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies page. oro.open.ac.uk www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 3 Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer Francesco Crea1, Akira Watahiki1,2, Luca Quagliata3, Hui Xue1, Larissa Pikor4, Abhijit Parolia1,5, Yuwei Wang1, Dong Lin1,2, Wan L. Lam4, William L. Farrar6, Takao Isogai7, Rudolf Morant8, Serenella Castori-Eppenberger3, Kim N. Chi2,9, Yuzhuo Wang1,2, and Cheryl D. Helgason1 1 Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada.
    [Show full text]